Biallelic NAA60 variants with impaired n-terminal acetylation capacity cause autosomal recessive primary familial brain calcifications.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
13 Mar 2024
Historique:
received: 14 11 2022
accepted: 23 02 2024
medline: 14 3 2024
pubmed: 14 3 2024
entrez: 14 3 2024
Statut: epublish

Résumé

Primary familial brain calcification (PFBC) is characterized by calcium deposition in the brain, causing progressive movement disorders, psychiatric symptoms, and cognitive decline. PFBC is a heterogeneous disorder currently linked to variants in six different genes, but most patients remain genetically undiagnosed. Here, we identify biallelic NAA60 variants in ten individuals from seven families with autosomal recessive PFBC. The NAA60 variants lead to loss-of-function with lack of protein N-terminal (Nt)-acetylation activity. We show that the phosphate importer SLC20A2 is a substrate of NAA60 in vitro. In cells, loss of NAA60 caused reduced surface levels of SLC20A2 and a reduction in extracellular phosphate uptake. This study establishes NAA60 as a causal gene for PFBC, provides a possible biochemical explanation of its disease-causing mechanisms and underscores NAA60-mediated Nt-acetylation of transmembrane proteins as a fundamental process for healthy neurobiological functioning.

Identifiants

pubmed: 38480682
doi: 10.1038/s41467-024-46354-0
pii: 10.1038/s41467-024-46354-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2269

Investigateurs

Henry Houlden (H)
Fowzan S Alkuraya (FS)

Informations de copyright

© 2024. The Author(s).

Références

Batla, A. et al. Deconstructing Fahr’s disease/syndrome of brain calcification in the era of new genes. Parkinsonism Relat. Disord. 37, 1–10 (2017).
pubmed: 28162874 doi: 10.1016/j.parkreldis.2016.12.024
Balck, A. et al. Genotype-phenotype relations in primary familial brain calcification: systematic MDSGene review. Mov. Disord. 36, 2468–2480 (2021).
pubmed: 34432325 doi: 10.1002/mds.28753
Nicolas, G., Charbonnier, C., Campion, D. & Veltman, J. A. Estimation of minimal disease prevalence from population genomic data: Application to primary familial brain calcification. Am. J. Med. Genet. B Neuropsychiatr. Genet. 177, 68–74 (2018).
pubmed: 29152850 doi: 10.1002/ajmg.b.32605
Wang, C. et al. Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. Nat. Genet. 44, 254–256 (2012).
pubmed: 22327515 doi: 10.1038/ng.1077
Legati, A. et al. Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. Nat. Genet. 47, 579–581 (2015).
pubmed: 25938945 pmcid: 4516721 doi: 10.1038/ng.3289
Keller, A. et al. Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. Nat. Genet. 45, 1077–1082 (2013).
pubmed: 23913003 doi: 10.1038/ng.2723
Nicolas, G. et al. Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. Neurology 80, 181–187 (2013).
pubmed: 23255827 doi: 10.1212/WNL.0b013e31827ccf34
Westenberger, A. & Klein, C. The genetics of primary familial brain calcifications. Curr. Neurol. Neurosci. Rep. 14, 490 (2014).
pubmed: 25212438 doi: 10.1007/s11910-014-0490-4
Yao, X. P. et al. Biallelic mutations in MYORG cause autosomal recessive primary familial brain calcification. Neuron 98, 1116–1123.e5 (2018).
pubmed: 29910000 doi: 10.1016/j.neuron.2018.05.037
Grangeon, L. et al. Biallelic MYORG mutation carriers exhibit primary brain calcification with a distinct phenotype. Brain 142, 1573–1586 (2019).
pubmed: 31009047 doi: 10.1093/brain/awz095
Schottlaender, L. V. et al. Bi-allelic JAM2 variants lead to early-onset recessive primary familial brain calcification. Am. J. Hum. Genet. 106, 412–421 (2020).
pubmed: 32142645 pmcid: 7058839 doi: 10.1016/j.ajhg.2020.02.007
Cen, Z. et al. Biallelic loss-of-function mutations in JAM2 cause primary familial brain calcification. Brain 143, 491–502 (2020).
pubmed: 31851307 doi: 10.1093/brain/awz392
Taglia, I., Bonifati, V., Mignarri, A., Dotti, M. T. & Federico, A. Primary familial brain calcification: update on molecular genetics. Neurol. Sci. 36, 787–794 (2015).
pubmed: 25686613 doi: 10.1007/s10072-015-2110-8
Zhao, M. et al. Loss of function of CMPK2 causes mitochondria deficiency and brain calcification. Cell Discov. 8, 128 (2022).
pubmed: 36443312 pmcid: 9705363 doi: 10.1038/s41421-022-00475-2
Wang, C. et al. [Molecular mechanism of idiopathic basal ganglia calcification]. Yi Chuan 37, 731–740 (2015).
pubmed: 26353387
Aksnes, H. et al. An organellar nalpha-acetyltransferase, naa60, acetylates cytosolic N termini of transmembrane proteins and maintains Golgi integrity. Cell Rep. 10, 1362–1374 (2015).
pubmed: 25732826 doi: 10.1016/j.celrep.2015.01.053
Aksnes, H., Marie, M. & Arnesen, T. Holding it together: Naa60 at the golgi. Oncotarget 6, 15726–15727 (2015).
pubmed: 26164078 pmcid: 4599222 doi: 10.18632/oncotarget.4779
Van Damme, P. et al. NatF contributes to an evolutionary shift in protein N-terminal acetylation and is important for normal chromosome segregation. PLoS Genet. 7, e1002169 (2011).
pubmed: 21750686 pmcid: 3131286 doi: 10.1371/journal.pgen.1002169
Aksnes, H., Ree, R. & Arnesen, T. Co-translational, post-translational, and non-catalytic roles of N-terminal acetyltransferases. Mol. Cell 73, 1097–1114 (2019).
pubmed: 30878283 pmcid: 6962057 doi: 10.1016/j.molcel.2019.02.007
Aksnes, H. et al. Molecular determinants of the N-terminal acetyltransferase Naa60 anchoring to the Golgi membrane. J. Biol. Chem. 292, 6821–6837 (2017).
pubmed: 28196861 pmcid: 5399128 doi: 10.1074/jbc.M116.770362
Laurie, S. et al. The RD-connect genome-phenome analysis platform: accelerating diagnosis, research, and gene discovery for rare diseases. Hum. Mutat. 43, 717–733 (2022).
pubmed: 35178824 pmcid: 9324157
Caulfield, M. et al. The 100,000 Genomes Project Protocol. https://doi.org/10.6084/m9.figshare.4530893.v4 . (2017).
Pedersen, B. S. & Quinlan, A. R. Who’s who? Detecting and resolving sample anomalies in human DNA sequencing studies with peddy. Am. J. Hum. Genet. 100, 406–413 (2017).
pubmed: 28190455 pmcid: 5339084 doi: 10.1016/j.ajhg.2017.01.017
Quinodoz, M. et al. AutoMap is a high performance homozygosity mapping tool using next-generation sequencing data. Nat. Commun. 12, 518 (2021).
pubmed: 33483490 pmcid: 7822856 doi: 10.1038/s41467-020-20584-4
Aksnes, H., Drazic, A., Marie, M. & Arnesen, T. First things first: vital protein marks by N-terminal acetyltransferases. Trends Biochem. Sci. 41, 746–760 (2016).
pubmed: 27498224 doi: 10.1016/j.tibs.2016.07.005
Støve, S. I. et al. Crystal structure of the golgi-associated human Nα-acetyltransferase 60 reveals the molecular determinants for substrate-specific acetylation. Structure 24, 1044–1056 (2016).
pubmed: 27320834 pmcid: 4938767 doi: 10.1016/j.str.2016.04.020
Beigl, T. B., Hellesvik, M., Saraste, J., Arnesen, T. & Aksnes, H. N-terminal acetylation of actin by NAA80 is essential for structural integrity of the Golgi apparatus. Exp. Cell Res. 390, 111961 (2020).
pubmed: 32209306 pmcid: 7308165 doi: 10.1016/j.yexcr.2020.111961
Nicolas, G. et al. Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification. Brain 136, 3395–3407 (2013).
pubmed: 24065723 doi: 10.1093/brain/awt255
Chelban, V. et al. MYORG-related disease is associated with central pontine calcifications and atypical parkinsonism. Neurol. Genet. 6, e399 (2020).
pubmed: 32211515 pmcid: 7073457 doi: 10.1212/NXG.0000000000000399
Jensen, N., Autzen, J. K. & Pedersen, L. Slc20a2 is critical for maintaining a physiologic inorganic phosphate level in cerebrospinal fluid. Neurogenetics 17, 125–130 (2016).
pubmed: 26660102 doi: 10.1007/s10048-015-0469-6
López-Sánchez, U. et al. Interplay between primary familial brain calcification-associated SLC20A2 and XPR1 phosphate transporters requires inositol polyphosphates for control of cellular phosphate homeostasis. J. Biol. Chem. 295, 9366–9378 (2020).
pubmed: 32393577 pmcid: 7363132 doi: 10.1074/jbc.RA119.011376
Sun, H. et al. Severe brain calcification and migraine headache caused by SLC20A2 and PDGFRB heterozygous mutations in a five-year-old Chinese girl. Mol. Genet. Genom. Med. 9, e1670 (2021).
doi: 10.1002/mgg3.1670
Ceylan, A. C. et al. Homozygous SLC20A2 mutations cause congenital CMV infection-like phenotype. Acta Neurol. Belg. 123, 1757–1761 (2022).
Aksnes, H., McTiernan, N. & Arnesen, T. NATs at a glance. J. Cell Sci. 136, jcs260766 (2023).
Arnesen, T. et al. Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans. Proc. Natl Acad. Sci. USA 106, 8157–8162 (2009).
pubmed: 19420222 pmcid: 2688859 doi: 10.1073/pnas.0901931106
Van Damme, P. et al. N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB. Proc. Natl Acad. Sci. USA 109, 12449–12454 (2012).
pubmed: 22814378 pmcid: 3412031 doi: 10.1073/pnas.1210303109
Van Damme, P. et al. A role for human N-alpha acetyltransferase 30 (Naa30) in maintaining mitochondrial integrity. Mol. Cell Proteomics 15, 3361–3372 (2016).
pubmed: 27694331 pmcid: 5098035 doi: 10.1074/mcp.M116.061010
Varland, S. et al. N-terminal acetylation shields proteins from degradation and promotes age-dependent motility and longevity. Nat. Commun. 14, 6774 (2023).
pubmed: 37891180 pmcid: 10611716 doi: 10.1038/s41467-023-42342-y
Linster, E. et al. Cotranslational N-degron masking by acetylation promotes proteome stability in plants. Nat. Commun. 13, 810 (2022).
pubmed: 35145090 pmcid: 8831508 doi: 10.1038/s41467-022-28414-5
Mueller, F. et al. Overlap of NatA and IAP substrates implicates N-terminal acetylation in protein stabilization. Sci. Adv. 7, eabc8590 (2021).
Van Damme, P. et al. Expanded in vivo substrate profile of the yeast N-terminal acetyltransferase NatC. J. Biol. Chem. 299, 102824 (2023).
pubmed: 36567016 doi: 10.1016/j.jbc.2022.102824
Starheim, K. K. et al. Knockdown of human N alpha-terminal acetyltransferase complex C leads to p53-dependent apoptosis and aberrant human Arl8b localization. Mol. Cell Biol. 29, 3569–3581 (2009).
pubmed: 19398576 pmcid: 2698767 doi: 10.1128/MCB.01909-08
Polevoda, B. & Sherman, F. NatC Nalpha-terminal acetyltransferase of yeast contains three subunits, Mak3p, Mak10p, and Mak31p. J. Biol. Chem. 276, 20154–20159 (2001).
pubmed: 11274203 doi: 10.1074/jbc.M011440200
Varshavsky, A. N-degron and C-degron pathways of protein degradation. Proc. Natl Acad. Sci. USA 116, 358–366 (2019).
pubmed: 30622213 pmcid: 6329975 doi: 10.1073/pnas.1816596116
Rope, A. F. et al. Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency. Am. J. Hum. Genet. 89, 28–43 (2011).
pubmed: 21700266 pmcid: 3135802 doi: 10.1016/j.ajhg.2011.05.017
Saunier, C. et al. Expanding the phenotype associated with NAA10-related N-terminal acetylation deficiency. Hum. Mutat. 37, 755–764 (2016).
pubmed: 27094817 pmcid: 5084832 doi: 10.1002/humu.23001
Cheng, H. et al. Phenotypic and biochemical analysis of an international cohort of individuals with variants in NAA10 and NAA15. Hum. Mol. Genet. 28, 2900–2919 (2019).
pubmed: 31127942 pmcid: 6736318 doi: 10.1093/hmg/ddz111
Ward, T. et al. Mechanisms of congenital heart disease caused by NAA15 Haploinsufficiency. Circ. Res. 128, 1156–1169 (2021).
pubmed: 33557580 pmcid: 8048381 doi: 10.1161/CIRCRESAHA.120.316966
Ritter, A. et al. Variants in NAA15 cause pediatric hypertrophic cardiomyopathy. Am. J. Med. Genet. A 185, 228–233 (2021).
pubmed: 33103328 doi: 10.1002/ajmg.a.61928
McTiernan, N. et al. Biochemical analysis of novel NAA10 variants suggests distinct pathogenic mechanisms involving impaired protein N-terminal acetylation. Hum. Genet. 141, 1355–1369 (2022).
pubmed: 35039925 pmcid: 9304055 doi: 10.1007/s00439-021-02427-4
Lyon, G. J. et al. Expanding the phenotypic spectrum of NAA10-related neurodevelopmental syndrome and NAA15-related neurodevelopmental syndrome. Eur. J. Hum. Genet. 31, 824–833 (2023).
pubmed: 37130971 pmcid: 10325952 doi: 10.1038/s41431-023-01368-y
Morrison, J. et al. Missense NAA20 variants impairing the NatB protein N-terminal acetyltransferase cause autosomal recessive developmental delay, intellectual disability, and microcephaly. Genet. Med. 23, 2213–2218 (2021).
pubmed: 34230638 pmcid: 8553619 doi: 10.1038/s41436-021-01264-0
D’Onofrio, G. et al. Novel biallelic variants expand the phenotype of NAA20-related syndrome. Clin. Genet. 104, 371–376 (2023).
Varland, S., Brønstad, K. M., Skinner, S. J. & Arnesen, T. A nonsense variant in the N-terminal acetyltransferase NAA30 may be associated with global developmental delay and tracheal cleft. Am. J. Med. Genet. A 191, 2402–241 (2023).
Muffels, I. J. J. et al. NAA80 bi-allelic missense variants result in high-frequency hearing loss, muscle weakness and developmental delay. Brain Commun. 3, fcab256 (2021).
pubmed: 34805998 pmcid: 8599064 doi: 10.1093/braincomms/fcab256
Drazic, A. et al. NAA80 is actin’s N-terminal acetyltransferase and regulates cytoskeleton assembly and cell motility. Proc. Natl. Acad. Sci. USA 115, 4399–4404 (2018).
pubmed: 29581253 pmcid: 5924898 doi: 10.1073/pnas.1718336115
Taglia, I. et al. Primary familial brain calcification: genetic analysis and clinical spectrum. Mov. Disord. 29, 1691–1695 (2014).
pubmed: 25284758 doi: 10.1002/mds.26053
Takashima, S. & Becker, L. E. Basal ganglia calcification in Down’s syndrome. J. Neurol. Neurosurg. Psychiatry 48, 61–64 (1985).
pubmed: 3156213 pmcid: 1028184 doi: 10.1136/jnnp.48.1.61
Vermersch, P., Leys, D., Pruvo, J. P., Clarisse, J. & Petit, H. Parkinson’s disease and basal ganglia calcifications: prevalence and clinico-radiological correlations. Clin. Neurol. Neurosurg. 94, 213–217 (1992).
pubmed: 1327610 doi: 10.1016/0303-8467(92)90091-G
Hashimoto, N. et al. Glial fibrillary tangles in diffuse neurofibrillary tangles with calcification. Acta Neuropathol. 106, 150–156 (2003).
pubmed: 12783246 doi: 10.1007/s00401-003-0715-0
Smedley, D. et al. 100,000 genomes pilot on rare-disease diagnosis in health care - preliminary report. N. Engl. J. Med. 385, 1868–1880 (2021).
pubmed: 34758253 doi: 10.1056/NEJMoa2035790
Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589–595 (2010).
pubmed: 20080505 pmcid: 2828108 doi: 10.1093/bioinformatics/btp698
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
pubmed: 20644199 pmcid: 2928508 doi: 10.1101/gr.107524.110
Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 11.10.1–33 (2013).
pubmed: 25431634
DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).
pubmed: 21478889 pmcid: 3083463 doi: 10.1038/ng.806
Danecek, P. & McCarthy, S. A. BCFtools/csq: haplotype-aware variant consequences. Bioinformatics 33, 2037–2039 (2017).
Yang, H. & Wang, K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat. Protoc. 10, 1556–1566 (2015).
pubmed: 26379229 pmcid: 4718734 doi: 10.1038/nprot.2015.105
Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
pubmed: 27535533 pmcid: 5018207 doi: 10.1038/nature19057
Yu, J. et al. SVRare: discovering disease-causing structural variants in the 100K Genomes Project. medRxiv, https://www.medrxiv.org/content/10.1101/2021.10.15.21265069v1 . (2022).
Seelow, D., Schuelke, M., Hildebrandt, F. & Nürnberg, P. HomozygosityMapper–an interactive approach to homozygosity mapping. Nucleic Acids Res. 37, W593–W599 (2009).
pubmed: 19465395 pmcid: 2703915 doi: 10.1093/nar/gkp369
Tompson, S. W. & Young, T. L. Assaying the effects of splice site variants by exon trapping in a mammalian cell line. Bio Protoc. 7, e2281 (2017).
pubmed: 28758139 pmcid: 5528174 doi: 10.21769/BioProtoc.2281
van der Knoop, M. M. et al. Biallelic ADAM22 pathogenic variants cause progressive encephalopathy and infantile-onset refractory epilepsy. Brain 145, 2301–2312 (2022).
pubmed: 35373813 pmcid: 9337806 doi: 10.1093/brain/awac116
Stove, S. I. et al. Crystal structure of the golgi-associated human nalpha-acetyltransferase 60 reveals the molecular determinants for substrate-specific acetylation. Structure 24, 1044–1056 (2016).
pubmed: 27320834 pmcid: 4938767 doi: 10.1016/j.str.2016.04.020
Foyn, H., Thompson, P. R. & Arnesen, T. DTNB-based quantification of in vitro enzymatic N-terminal acetyltransferase activity. Methods Mol. Biol. 1574, 9–15 (2017).
pubmed: 28315240 doi: 10.1007/978-1-4939-6850-3_2
Starheim, K. K. et al. Identification of the human N(alpha)-acetyltransferase complex B (hNatB): a complex important for cell-cycle progression. Biochem. J. 415, 325–331 (2008).
pubmed: 18570629 doi: 10.1042/BJ20080658
Taglia, I. et al. Primary familial brain calcification with a novel SLC20A2 mutation: analysis of PiT-2 expression and localization. J. Cell Physiol. 233, 2324–2331 (2018).
pubmed: 28722801 doi: 10.1002/jcp.26104
Cassinari, K. et al. Haploinsufficiency of the primary familial brain calcification gene SLC20A2 mediated by disruption of a regulatory element. Mov. Disord. 35, 1336–1345 (2020).
pubmed: 32506582 doi: 10.1002/mds.28090
Human genomics. The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648–660 (2015).
doi: 10.1126/science.1262110
Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118–127 (2007).
pubmed: 16632515 doi: 10.1093/biostatistics/kxj037
Botia, J. A. et al. An additional k-means clustering step improves the biological features of WGCNA gene co-expression networks. BMC Syst. Biol. 11, 47 (2017).
pubmed: 28403906 pmcid: 5389000 doi: 10.1186/s12918-017-0420-6
Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).
pubmed: 19114008 pmcid: 2631488 doi: 10.1186/1471-2105-9-559
Reimand, J., Kull, M., Peterson, H., Hansen, J. & Vilo, J. g:Profiler–a web-based toolset for functional profiling of gene lists from large-scale experiments. Nucleic Acids Res. 35, W193–W200 (2007).
pubmed: 17478515 pmcid: 1933153 doi: 10.1093/nar/gkm226

Auteurs

Viorica Chelban (V)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK. v.chelban@ucl.ac.uk.
Neurobiology and Medical Genetics Laboratory, "Nicolae Testemitanu" State University of Medicine and Pharmacy, 165, Stefan cel Mare si Sfant Boulevard, MD, 2004, Chisinau, Republic of Moldova. v.chelban@ucl.ac.uk.

Henriette Aksnes (H)

Department of Biomedicine, University of Bergen, Bergen, Norway. henriette.aksnes@uib.no.

Reza Maroofian (R)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.

Lauren C LaMonica (LC)

Department of Cell Biology, Yale School of Medicine, New Haven, CT, USA.

Luis Seabra (L)

Université Paris Cité, Imagine Institute, Laboratory of Neurogenetics and Neuroinflammation, INSERM UMR 1163, Paris, France.

Anette Siggervåg (A)

Department of Biomedicine, University of Bergen, Bergen, Norway.

Perrine Devic (P)

Hospices Civils de Lyon, Groupement Hospitalier Sud, Service d'Explorations Fonctionnelles Neurologiques, Lyon, France.

Hanan E Shamseldin (HE)

Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Jana Vandrovcova (J)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.

David Murphy (D)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.

Anne-Claire Richard (AC)

Univ Rouen Normandie, Inserm U1245, CHU Rouen, Department of Genetics and CNRMAJ, F-76000, Rouen, France.

Olivier Quenez (O)

Univ Rouen Normandie, Inserm U1245, CHU Rouen, Department of Genetics and CNRMAJ, F-76000, Rouen, France.

Antoine Bonnevalle (A)

Univ Rouen Normandie, Inserm U1245, CHU Rouen, Department of Genetics and CNRMAJ, F-76000, Rouen, France.

M Natalia Zanetti (MN)

Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.

Rauan Kaiyrzhanov (R)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
South Kazakhstan Medical Academy Shymkent, Shymkent, 160019, Kazakhstan.

Vincenzo Salpietro (V)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.

Stephanie Efthymiou (S)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.

Lucia V Schottlaender (LV)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
Instituto de Investigaciones en Medicina Traslacional (IIMT), CONICET-Universidad Austral, Av. Juan Domingo Perón 1500, B1629AHJ, Pilar, Argentina.
Instituto de medicina genómica (IMeG), Hospital Universitario Austral, Universidad Austral, Av. Juan Domingo Perón 1500, B1629AHJ, Pilar, Argentina.

Heba Morsy (H)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
Department of Human Genetics, Medical Research Institute, Alexandria University, Alexandria, Egypt.

Annarita Scardamaglia (A)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.

Ambreen Tariq (A)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.

Alistair T Pagnamenta (AT)

Oxford NIHR Biomedical Research Centre, Wellcome Centre for Human Genetics, Oxford, United Kingdom.

Ajia Pennavaria (A)

Department of Biomedicine, University of Bergen, Bergen, Norway.

Liv S Krogstad (LS)

Department of Biomedicine, University of Bergen, Bergen, Norway.

Åse K Bekkelund (ÅK)

Department of Biomedicine, University of Bergen, Bergen, Norway.

Alessia Caiella (A)

Department of Biomedicine, University of Bergen, Bergen, Norway.

Nina Glomnes (N)

Department of Biomedicine, University of Bergen, Bergen, Norway.
Department of Clinical Science, University of Bergen, 5020, Bergen, Norway.

Kirsten M Brønstad (KM)

Department of Biomedicine, University of Bergen, Bergen, Norway.

Sandrine Tury (S)

Institut de Recherche en Infectiologie de Montpellier, Université de Montpellier, CNRS, Montpellier, France.

Andrés Moreno De Luca (A)

Department of Radiology, Autism & Developmental Medicine Institute, Geisinger, Lewisburg, PA, USA.
Department of Radiology, Neuroradiology Section, Kingston Health Sciences Centre, Queen's University Faculty of Health Sciences, Kingston, Ontario, Canada.

Anne Boland-Auge (A)

Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), 91057, Evry, France.

Robert Olaso (R)

Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), 91057, Evry, France.

Jean-François Deleuze (JF)

Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), 91057, Evry, France.

Mathieu Anheim (M)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.
Strasbourg Federation of Translational Medicine (FMTS), Strasbourg University, Strasbourg, France.
INSERM-U964; CNRS-UMR7104, University of Strasbourg, Illkirch-Graffenstaden, France.

Benjamin Cretin (B)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.
Strasbourg Federation of Translational Medicine (FMTS), Strasbourg University, Strasbourg, France.
INSERM-U964; CNRS-UMR7104, University of Strasbourg, Illkirch-Graffenstaden, France.

Barbara Vona (B)

Institute of Human Genetics, University Medical Center Göttingen, 37073, Göttingen, Germany.
Institute for Auditory Neuroscience and InnerEarLab, University Medical Center Göttingen, 37075, Göttingen, Germany.

Fahad Alajlan (F)

Department of Neuroscience Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Firdous Abdulwahab (F)

Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Jean-Luc Battini (JL)

Institut de Recherche en Infectiologie de Montpellier, Université de Montpellier, CNRS, Montpellier, France.

Rojan İpek (R)

Paediatric Neurology, Faculty of Medicine, Dicle University, Diyarbakır, Turkey.

Peter Bauer (P)

Centogene GmbH, Am Strande 7, 18055, Rostock, Germany.

Giovanni Zifarelli (G)

Centogene GmbH, Am Strande 7, 18055, Rostock, Germany.

Serdal Gungor (S)

Inonu University, Faculty of Medicine, Turgut Ozal Research Center, Department of Pediatrics, Division of Pediatric Neurology, Malatya, Turkey.

Semra Hiz Kurul (SH)

Dokuz Eylul University, School of Medicine, Department of Paediatric Neurology, Izmir, Turkey.

Hanns Lochmuller (H)

Children's Hospital of Eastern Ontario Research Institute and Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, Canada.
Brain and Mind Research Institute, University of Ottawa, Ottawa, Canada.
Department of Neuropediatrics and Muscle Disorders, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany.

Sahar I Da'as (SI)

Department of Human Genetics, Sidra Medicine, Doha, Qatar.
College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.

Khalid A Fakhro (KA)

Department of Human Genetics, Sidra Medicine, Doha, Qatar.
College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.
Weill Cornell Medical College, Doha, Qatar.

Alicia Gómez-Pascual (A)

Department of Information and Communications Engineering, University of Murcia, Campus Espinardo, 30100, Murcia, Spain.

Juan A Botía (JA)

Department of Information and Communications Engineering, University of Murcia, Campus Espinardo, 30100, Murcia, Spain.

Nicholas W Wood (NW)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
Neurogenetics Laboratory, The National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK.

Rita Horvath (R)

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

Andreas M Ernst (AM)

Department of Cell Biology, Yale School of Medicine, New Haven, CT, USA.
School of Biological Sciences, Department of Cell and Developmental Biology, University of California San Diego, La Jolla, CA, USA.

James E Rothman (JE)

Department of Cell Biology, Yale School of Medicine, New Haven, CT, USA.
Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.

Meriel McEntagart (M)

Medical Genetics Department, St George's University Hospitals, London, SWI7 0RE, UK.

Yanick J Crow (YJ)

Université Paris Cité, Imagine Institute, Laboratory of Neurogenetics and Neuroinflammation, INSERM UMR 1163, Paris, France.
MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.

Fowzan S Alkuraya (FS)

Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.

Gaël Nicolas (G)

Univ Rouen Normandie, Inserm U1245, CHU Rouen, Department of Genetics and CNRMAJ, F-76000, Rouen, France.

Thomas Arnesen (T)

Department of Biomedicine, University of Bergen, Bergen, Norway. thomas.arnesen@uib.no.
Department of Surgery, Haukeland University Hospital, Bergen, Norway. thomas.arnesen@uib.no.

Henry Houlden (H)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK. h.houlden@ucl.ac.uk.
Neurogenetics Laboratory, The National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK. h.houlden@ucl.ac.uk.

Classifications MeSH